Structured evidence table for Myo-Inositol Cardiometabolic Markers Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Myo-Inositol Cardiometabolic Markers Randomized Trial | 1 2 3 4 Polycystic ovary syndrome (PCOS) is among the most frequent endocrine disorders in women of reproductive age and is strongly associated with multiple cardiometabolic disturbances. | 4 | Muacevic Alexander (2026) | Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | While these approaches can reduce symptoms, they mostly do not address the underlying endocrine or metabolic disturbances and may be associated with adverse effects, including gastrointestinal discomfort, weight gain, and fatigue [,]. | 4 | Muacevic Alexander (2026) | Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | Increasing evidence also points to the benefits of curcumin, a polyphenolic compound from turmeric, which down-regulates inflammatory mediators and oxidative stress, thereby improving insulin action []. | 4 | Muacevic Alexander (2026) | Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | Globally, the condition affects roughly 4-20% of women, underscoring its significance as a public-health concern [,]. | 4 | Muacevic Alexander (2026) | Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | Midlife is characterized by a rapid decrease in endogenous estrogen levels for women which is thought to increase risk for cardiometabolic disease and neurocognitive decline. | 4 | Foret JT (2022) | Influence of endogenous estrogen on a network model of female brain integrity. |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | Networks consisted of known biomarkers of risk for late-life cognitive decline: the five components of MetS; Brain-predicted age difference calculated on gray and white matter volume; white matter hyperintensities; Default Mode Network functional connectivity; cerebral concentrations of N -acetyl aspartate, glutamate and myo-inositol; and serum concentrations of estradiol. | 4 | Foret JT (2022) | Influence of endogenous estrogen on a network model of female brain integrity. |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | A negative expected influence indicates that higher levels of estradiol would be expected to decrease the number of relationships in the model, which is thought to indicate lower risk. | 4 | Foret JT (2022) | Influence of endogenous estrogen on a network model of female brain integrity. |
| Myo-Inositol Cardiometabolic Markers Randomized Trial | Recent reports document sex differences in midlife brain integrity and metabolic health, such that more relationships are detectable between metabolic syndrome (MetS) components and markers of brain health in females than in males. | 4 | Foret JT (2022) | Influence of endogenous estrogen on a network model of female brain integrity. |
Source documents